An Israeli breakthrough in the treatment of cancer has the international medical community taking notice. Developed by Tel Aviv University Professors Rimona Margalit and Dan Peer, this novel drug-delivery platform involves the use of “GAGomers,” a new class of nanoparticles (coated with glycosaminoglycan, or GAGs, a polysugar) that specifically target tumors and blood cancers based on a biomarker expressed on malignant tissue.
For their groundbreaking work, Margalit and Peer were granted the prestigious Untold News Award in New York City in November.
But it was already back in 2010 that leading Israeli venture capital firm Pontifax established the bio-pharmaceutical company Quiet Therapeutics, to make Margalit’s and Peer’s innovative platform accessible and marketable to oncology patients and their doctors.
Currently funded by Pontifax and Arkin Holdings, the biotech startup initially operated within the incubators program of the Office of the Chief Scientist, the arm of the Economy Ministry charged with fostering industrial research and development in Israel.
More...
